Cardiovascular and behavioural effects induced by naloxone-precipitated morphine withdrawal in rat: Characterization with tachykinin antagonists

Neuropeptides

Volumn 37, Issue 6, 2003, Pages 345-354

  Michaud, Nadine ^a   Couture, Réjean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Behaviour; Blood pressure; Heart rate; Morphine withdrawal; Tachykinins

Indexed keywords

LY 306740; MORPHINE; NALOXONE; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; R 820; SAREDUTANT; TACHYKININ RECEPTOR AGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BLOOD PRESSURE MONITORING; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG POTENTIATION; DRUG WITHDRAWAL; GROOMING; HEART RATE VARIABILITY; MALE; NONHUMAN; PERSONAL HYGIENE; PRIORITY JOURNAL; RAT; REARING; SNIFFING; WITHDRAWAL SYNDROME;

CANIS FAMILIARIS;

EID: 0347755619     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2003.09.003     Document Type: Article

References (45)

1. 2) receptor revisited with SR48968, a potent non-peptide antagonist. Biochem. Biophys. Res. Commun. 184, 1418-1424.
2. Bergström, L., Sakurada, T., Terenius, L., 1984. Substance P levels in various regions of the rat central nervous system after acute and chronic morphine treatment. Life Sci. 35, 2375-2382.
3. Brent, P.J., Johnston, P.A., Chahl, L.A., 1987. Plasma catecholamine concentrations during morphine withdrawal in conscious guinea-pigs. Clin. Exp. Pharmacol. Physiol. 14, 623-631.
4. Buccafusco, J.J., Shuster, L.C., 1997. Effect of intrathecal pretreatment with the neurokinin receptor antagonist CP-99994 on the expression of naloxone-precipitated morphine withdrawal symptoms. Brain Res. Bull. 43, 321-326.
5. 1 receptor antagonists in the rat. Br. J. Pharmacol. 127, 717-728.
6. 3 receptor antagonists in the conscious rat. Br. J. Pharmacol. 122, 643-654.
7. Chan, R., Irvine, R., White, J., 1999. Cardiovascular changes during morphine administration and spontaneous withdrawal in the rat. Eur. J. Pharmacol. 368, 25-33.
8. Couture, R., Toma, N., Barbot, L., 2000. SR142801 behaves as a tachykinin NK-3 receptor agonist on a spinal nociceptive reflex in the rat. Life Sci. 66, 51-65.
9. Couture, R., Picard, P., Poulat, P., Prat, A., 1995. Characterization of the tachykinin receptors involved in spinal and supraspinal cardiovascular regulation. Can. J. Physiol. Pharmacol. 73, 892-902.
10. Couture, R., Laneuville, O., Guimond, C., Drapeau, G., Regoli, D., 1989. Characterization of the peripheral action of neurokinins and neurokinin receptor selective agonists on the rat cardiovascular system. Naunyn-Schm. Arch. Pharmacol. 340, 547-557.
11. Culman, J., Klee, S., Ohlendorf, C., Unger, Th., 1997. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J. Pharmacol. Exp. Ther. 280, 238-246.
12. 3 receptor. Life Sci. 56, PL27-PL32.
13. 2) receptor. Life Sci. 50, 101-106.
14. Himmelsbach, C.K., 1942. Clinical studies of drug addiction: physical dependence, withdrawal and recovery. Arch. Intern. Med. 69, 766-772.
15. Hipskind, P.A., Howbert, J.J., Bruns, R.F., Cho, S.S., Crowell, T.A., Foreman, M.M., Gehlert, D.R., Iyengar, S., Johnson, K.W., Krushinski, J.H., Li, D.L., Lobb, K.L., Mason, N.R., Muehl, B.S., Nixon, J.A., Phebus, L.A., Regoli, D., Simmons, R.M., Threlkeld, P.G., Waters, D.C., Gitter, B.D., 1996. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J. Med. Chem. 39, 736-748.
16. Itoi, K., Tschöpe, C., Jost, N., Culman, J., Lebrun, C., Stauss, B., Unger, T., 1992. Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioral responses in conscious rats. Eur. J. Pharmacol. 219, 435-444.
17. Johnston, P.A., Chahl, L.A., 1991. Tachykinin antagonists inhibit the morphine withdrawal response in guinea-pigs. Naunyn-Schm. Arch. Pharmacol. 343, 283-288.
18. Johnston, P.A., Chahl, L.A., 1993. Neurokinin-1, -2 and -3 receptors are candidates for a role in the opiate withdrawal response in guinea-pigs. Regul. Peptides 46, 376-378.
19. Kolb, L., Himmelsbach, C.K., 1938. Clinical studies of drug addiction, III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am. J. Psychiatry 94, 759-799.
20. Laorden, M.L., Milanés, M.V., Chapleur-Château, M., Burlet, A., 1998. Changes in oxytocin content in rat brain during morphine withdrawal. Neuropeptides 32, 67-71.
21. Laschka, E., Herz, A., Bläsig, J., 1976a. Sites of action of morphine involved in the development of physical dependence in rats. I. Comparison of precipitated morphine withdrawal after intraperitoneal and intraventricular injection of morphine antagonists. Psychopharmacologia 46, 133-139.
22. Laschka, E., Teschemacher, H.J., Mehraein, P., Herz, A., 1976b. Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas. Psychopharmacologia 46, 141-147.
23. Lessard, A., Couture, R., 2001. Anti-hypertensive effect induced by intracerebral injection of tachykinin NK-3 receptor antagonists in hypertensive rats. In: 31st Annual Meeting of Society for Neuroscience, San Diego, CA, USA, November 10-15, 2001 (Abstract 837.7).
24. Li, Y., Tian, S., Douglas, S.D., Ho, W.-Z., 2000. Morphine up-regulates expression of substance P and its receptor in human blood mononuclear phagocytes and lymphocytes. Cell. Immunol. 205, 120-127.
25. Ma, W., Zheng, W.-H., Kar, S., Quirion, R., 2000. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience 99, 529-539.
26. Maggi, C.A., Patacchini, R., Rovero, P., Giachetti, A., 1993. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol. 13, 23-93.
27. Maldonado, R., Girdlestone, D., Roques, B.P., 1993. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci. Lett. 156, 135-140.
28. Maldonado, R., Stinus, L., Gold, L.H., Koob, G.F., 1992. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 61, 669-677.
29. Marshall, D.C., Buccafusco, J.J., 1985. Supraspinal and spinal mediation of naloxone-induced morphine withdrawal in rats. Brain Res. 329, 131-142.
30. Martin, W.R., Wikler, A., Eades, C.G., Pescor, F.T., 1963. Tolerance to and physical dependence on morphine in rats. Psychopharmacologia 4, 247-260.
31. Michaud, N., 2001. Implication des récepteurs centraux des tachykinines lors d'un sevrage à la morphine chez le rat. M.Sc. Thesis, Université de Montréal, pp. 1-104.
32. Morton, C.R., Hutchison, W.D., Hendry, I.A., 1991. Intraspinal release of substance P and calcitonin gene-related peptide during opiate dependence and withdrawal. Neuroscience 43, 593-600.
33. Murtra, P., Sheasby, A.M., Hunt, S.P., De Felipe, C., 2000. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405, 180-183.
34. Otsuka, M., Yoshioka, K., 1993. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73, 229-308.
35. Picard, P., Regoli, D., Couture, R., 1994. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists. Br. J. Pharmacol. 112, 240-249.
36. Powell, K.J., Ma, W., Sutak, M., Doods, H., Quirion, R., Jhamandas, K., 2000. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br. J. Pharmacol. 131, 875-884.
37. Regoli, D., Boudon, A., Fauchère, J.L., 1994. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46, 551-599.
38. Sharpe, L.G., Jaffe, J.H., 1986. Neonatal capsaicin modifies morphine withdrawal signs in the rat. Neurosci. Lett. 71, 213-218.
39. Szikszay, M., Benedek, G., Obal, F., 1983. Morphine tolerance and withdrawal in capsaicin-pretreated rats. Life Sci. 33 (Suppl. 1), 377-380.
40. Trafton, J.A., Abbadie, C., Marchand, S., Mantyh, P.W., Basbaum, A.I., 1999. Spinal opioid analgesia: how critical is the regulation of substance P signaling ? J. Neurosci. 19, 9642-9653.
41. 2 receptors in the rat. Br. J. Pharmacol. 107, 750-755.
42. 2+ entry. Brain Res. 425, 101-105.
43. Unger, T., Carolus, S., Demmert, G., Ganten, D., Lang, R.E., Maser-Gluth, C., Steinberg, H., Veelken, H., 1988. Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization. Circ. Res. 63, 812-820.
44. Wei, E.T., 1983. Inhibition of shaking movements in rats by central administration of cholinergic and adrenergic agents. Psychopharmacol. 81, 111-114.
45. Zhou, Q., Liu, Z., Ray, A., Huang, W., Karlsson, K., Nyberg, F., 1998. Alteration in the brain content of substance P (1-7) during withdrawal in morphine-dependent rats. Neuropharmacology 37, 1545-1552.